Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis Background: Adalimumab, a monoclonal antibody targeting TNFα, treats autoimmune diseases but induces anti-drug antibodies in 30–60% of patients, reducing its efficacy. Objective: This study investigates molecular mimicry as a mechanism behind this immunogenicity, where bacterial immunoglobulin domains structurally resemble adalimumab’s light chain, triggering immune responses. Methods: Using PSI-BLASTp and IBIVU Praline, there are 40 bacterial antigens homologous to adalimumab, with eight clinically relevant strains. Results: Structural analysis revealed 94% amino acid identity between the immunoglobulin domain of Escherichia coli strain B1 and adalimumab’s light chain, and 89.67% similarity with Corynebacterium pyruviciproducens. Root Mean Square Deviation values confirmed strong structural homology. Additionally, five cross-reactive B-cell epitopes were predicted, suggesting overlapping surfaces that may promote immune cross-reactivity and anti-drug antibody development. Conclusions: These findings emphasize the role of bacterial immunoglobulin domains in adalimumab immunogenicity and highlight further need for experimental validation and improved strategies to reduce immune responses in biological therapies.

Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis #Adalimumab #Immunogenicity #AutoimmuneDiseases #BiologicTherapy #MolecularMimicry

utility, and the development of drugs targeting autoantibodies.
#piME/CFS #pcME/CFS #PCS #EBV #Autoimmunity #MolecularMimicry

Frontiers | Exploratory study on autoantibodies to arginine-rich human peptides mimicking Epstein-Barr virus in women with post-COVID and myalgic encephalomyelitis/chronic fatigue syndrome IntroductionEpstein-Barr virus (EBV) infection is a well-established trigger and risk factor for both myalgic encephalomyelitis/chronic fatigue syndrome (ME/...

Exploratory study on autoantibodies to arginine-rich human peptides mimicking Epstein-Barr virus in women with post-COVID and myalgic encephalomyelitis/chronic fatigue syndrome @scheibenbogen.bsky.social et al.
#EBV #MolecularMimicry #ME/CFS #PCS #Autoimmunity

📣 Online now - the Review "Molecular mimicry: ecology, evolution, and applications of doppelgänger peptides" from Thomas Koch, Samuel Robinson, and Helena Safavi-Hemami.

#MolecularMimicry #Hormones #Neuropeptides #Semiochemicals #Toxins #Venoms

Read it here: authors.elsevier.com/sd/article/S...

#Medsky🧪#IDSky #immunosky #publichealth #Molecularmimicry is one mechanism by which an infectious pathogen may trigger an #autoimmunedisease in a human subject and occurs when foreign- and self-peptides contain similar epitopes that activate an autoimmune response in a susceptible individual.

Timothy Henrich UCSF LIINC study Post Viral Syndrome(s) Epstein Barr Virus youtube.com/watch?v=6wik... #EBV #Inflammation #PostViralSequelae #MS #MolecularMimicry

Cross-reactive T cells link SARS-CoV-2 to autoimmune triggers in MIS-C Research identifies cross-reactive T cells targeting both SARS-CoV-2 and human SNX8 protein, providing insights into the autoimmune mechanisms driving MIS-C in children.

Cross-reactive T cells link SARS-CoV-2 to autoimmune triggers in MIS-C 🧬🧪👶 www.news-medical.net/news/2024080... #MIS-C #Autoimmunity #Pediatrics #SARSCoV2 #TCells #ImmuneSystem #MolecularMimicry #SNX8 #COVID19Research #Immunology @natureportfolio.bsky.social